Please assess the completion status of the following clinical trial:

Trial Title: Study of a Tetravalent Dengue Vaccine in Healthy Adults in Australia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 18 to 60 years on the day of inclusion.~* Informed consent form was signed and dated.~* Able to attend all scheduled visits and to comply with all trial procedures.~* For a woman of childbearing potential, use of an effective method of contraception, or abstinence from at least 4 weeks prior to the first vaccination until at least 4 weeks after the last vaccination (i.e., for 14 months).~Exclusion Criteria:~* Known pregnancy, or a positive urine pregnancy test.~* History of flavivirus infection or vaccination or prolonged habitation in a dengue endemic area.~* Currently breastfeeding a child.~* Participation in another clinical trial investigating a vaccine, drug, medical device, or medical procedure in the 4 weeks preceding the first trial vaccination.~* Planned participation in another clinical trial during the present trial period.~* Planned receipt of any vaccine in the 4 weeks following any trial vaccination, except for pandemic influenza vaccination.~* Receipt of blood or blood-derived products in the past 3 months, which might interfere with assessment of the immune response.~* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months).~* Self-reported seropositivity for human immunodeficiency virus (HIV).~* Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to the vaccine used in the trial or to a vaccine containing any of the same substances.~* Deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized involuntarily.~* Current alcohol abuse or drug addiction that might interfere with the ability to comply with trial procedures.~* Chronic illness that, in the opinion of the Investigator, is at a stage where it might interfere with trial conduct or completion.~* Identified as a site employee of the Investigator or study center, with direct involvement in the proposed study or other studies under the direction of that Investigator or study center, as well as family members (i.e., immediate, husband, wife and their children, adopted or natural) of the site employees or the Investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- CYD Dengue Vaccine Phase III Lot 1 (Type: EXPERIMENTAL): Participants received 3 doses of CYD dengue vaccine (Phase III Lot 1), one each at Day 0 (vaccination 1),Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
- CYD Dengue vaccine - Phase III Lot 2 (Type: EXPERIMENTAL): Participants received 3 doses of CYD dengue vaccine (Phase III Lot 2) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
- CYD Dengue vaccine - Phase III Lot 3 (Type: EXPERIMENTAL): Participants received 3 doses of CYD dengue vaccine (Phase III Lot 3) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
- CYD Dengue vaccine - Phase II Lot (Type: EXPERIMENTAL): Participants received 3 doses of CYD dengue vaccine (Phase II Lot) one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo matched to CYD dengue vaccine, one each at Day 0 (vaccination 1), Month 6 (vaccination 2), and Month 12 (vaccination 3), subcutaneously.

Based on this trial design, predict the completion outcome and termination type (if applicable).